Telo Genomics Corp

Healthcare CA TELO

0.045CAD
0.00(0%)

Last update at 2026-06-23T19:57:00Z

Day Range

0.040.04

LowHigh

52 Week Range

0.040.12

LowHigh

Fundamentals

Previous Close 0.04
Market Cap5.02M
Volume123600
P/E Ratio-
Dividend Yield-%
EBITDA-1.87296M
Revenue TTM0.00000M
Revenue Per Share TTM-
Gross Profit TTM 0.00000M
Diluted EPS TTM-0.02

Overview
Financials
Peer Comparison
Reports
Stock Research & News
Profile

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown	2025-06-30	2024-06-30	2023-06-30	2022-06-30	2021-06-30
Type	yearly	yearly	yearly	yearly	yearly
Date	2025-06-30	2024-06-30	2023-06-30	2022-06-30	2021-06-30
Income before tax	-2.71875M	-2.71301M	-2.82077M	-2.11045M	-1.06996M
Minority interest	-	-	-	-	-
Net income	-2.71875M	-2.71301M	-2.82077M	-2.11045M	-1.06996M
Selling general administrative	1.31M	1.36M	1.46M	0.99M	0.65M
Selling and marketing expenses	-	-	-	-	-
Gross profit	-	-	-0.03311M	-0.05696M	-0.06223M
Reconciled depreciation	0.01M	0.04M	0.03M	0.06M	0.06M
Ebit	-	-	-2.82077M	-2.11045M	-1.07371M
Ebitda	-	-	-2.78766M	-2.05350M	-1.01148M
Depreciation and amortization	-	-	0.03M	0.06M	0.06M
Non operating income net other	-	-	-	-	-
Operating income	-2.70238M	-2.72301M	-2.82077M	-2.11045M	-1.07371M
Other operating expenses	-	-	2.82M	2.11M	1.26M
Interest expense	-	-	0.00521M	0.00539M	0.00000M
Tax provision	-	-	-	-	-
Interest income	-	-	-	-	-
Net interest income	-	-	-	-	0.00000M
Extraordinary items	-	-	-	-	-
Non recurring	-	-	-	-	-
Other items	-	-	-	-	-
Income tax expense	-	-	-0.00520M	-0.00539M	0.18M
Total revenue	0.00000M	0.00000M	0.00000M	0.00000M	0.00000M
Total operating expenses	2.70M	2.72M	2.82M	2.11M	1.26M
Cost of revenue	-	-	0.03M	0.06M	0.06M
Total other income expense net	-0.01637M	0.01000M	-0.00520M	-0.00539M	0.19M
Discontinued operations	-	-	-	-	-
Net income from continuing ops	-2.71875M	-2.71301M	-2.82077M	-2.11045M	-1.06996M
Net income applicable to common shares	-	-	-	-2.11045M	-1.06996M
Preferred stock and other adjustments	-	-	-	-	-

Breakdown	2025-06-30	2024-06-30	2023-06-30	2022-06-30	2021-06-30
Type	yearly	yearly	yearly	yearly	yearly
Date	2025-06-30	2024-06-30	2023-06-30	2022-06-30	2021-06-30
Total assets	0.91M	0.97M	2.93M	2.83M	3.84M
Intangible assets	-	-	-	-	-
Earning assets	-	-	-	-	-
Other current assets	-	-	-	-	-
Total liab	0.40M	0.38M	0.31M	0.23M	0.15M
Total stockholder equity	0.51M	0.59M	2.61M	2.60M	3.69M
Deferred long term liab	-	-	-	-	-
Other current liab	-	-	-	-	-
Common stock	-	-	-	19.11M	18.23M
Capital stock	24.57M	22.35M	21.69M	19.11M	18.23M
Retained earnings	-30.54998M	-27.83123M	-25.11822M	-22.29744M	-20.18699M
Other liab	-	-	-	-	-
Good will	-	-	-	-	-
Other assets	-	-	-	-	-
Cash	0.79M	0.80M	2.67M	2.69M	3.64M
Cash and equivalents	-	-	-	-	-
Total current liabilities	0.40M	0.38M	0.28M	0.19M	0.11M
Current deferred revenue	-	-	-	-	-
Net debt	-	-	-	-	-
Short term debt	-	-	-	-	-
Short long term debt	-	-	-	-	-
Short long term debt total	-	-	-	-	-
Other stockholder equity	-	-	-	-	-
Property plant equipment	-	-	-	0.02M	0.06M
Total current assets	0.89M	0.92M	2.84M	2.79M	3.76M
Long term investments	-	-	-	-	-
Net tangible assets	-	-	-	2.58M	3.61M
Short term investments	-	-	-	-	-
Net receivables	0.03M	0.03M	0.06M	0.04M	0.10M
Long term debt	-	-	0.03M	0.04M	0.04M
Inventory	-	-	-	-	-
Accounts payable	-	-	-	0.19M	0.10M
Total permanent equity	-	-	-	-	-
Noncontrolling interest in consolidated entity	-	-	-	-	-
Temporary equity redeemable noncontrolling interests	-	-	-	-	-
Accumulated other comprehensive income	-	-	-	-	-
Additional paid in capital	-	-	-	-	-
Common stock total equity	-	-	-	-	-
Preferred stock total equity	-	-	-	-	-
Retained earnings total equity	-	-	-	-	-
Treasury stock	-	-	-	-	-
Accumulated amortization	-	-	-	-	-
Non currrent assets other	-	-	-	-	-
Deferred long term asset charges	-	-	-	-	-
Non current assets total	0.02M	0.05M	0.08M	0.05M	0.08M
Capital lease obligations	-	-	-	-	-
Long term debt total	-	-	-	-	-

Breakdown	2025-06-30	2024-06-30	2023-06-30	2022-06-30	2021-06-30
Type	yearly	yearly	yearly	yearly	yearly
Date	2025-06-30	2024-06-30	2023-06-30	2022-06-30	2021-06-30
Investments	-0.00325M	-0.00511M	-0.06906M	-0.02519M	-0.00931M
Change to liabilities	-	-	-	0.08M	-0.04317M
Total cashflows from investing activities	-	-	-	-0.02519M	-0.00931M
Net borrowings	0.00000M	-	-	-	-0.01500M
Total cash from financing activities	2.33M	0.59M	2.68M	0.88M	3.83M
Change to operating activities	-	-	-	-0.02807M	0.04M
Net income	-2.71875M	-2.71301M	-2.82077M	-2.11045M	-1.06996M
Change in cash	-0.00673M	-1.87723M	-0.01972M	-0.94354M	2.72M
Begin period cash flow	0.80M	2.67M	2.69M	3.64M	0.92M
End period cash flow	0.79M	0.80M	2.67M	2.69M	3.64M
Total cash from operating activities	-2.32873M	-2.45916M	-2.62956M	-1.79499M	-1.10453M
Issuance of capital stock	2.55M	0.65M	2.83M	0.20M	2.09M
Depreciation	0.01M	0.04M	0.03M	0.06M	0.06M
Other cashflows from investing activities	-	-	-	-	-
Dividends paid	-	-	-	-	-
Change to inventory	-	-	-	-	-
Change to account receivables	-	-	-0.02579M	0.06M	-0.04747M
Sale purchase of stock	-	-	-	-	-
Other cashflows from financing activities	-	-	-0.14747M	0.68M	1.75M
Change to netincome	-	-	-	0.15M	-0.04568M
Capital expenditures	0.00325M	0.00511M	0.07M	0.03M	0.00931M
Change receivables	-	-	-	-	-
Cash flows other operating	-	-	-	-	-
Exchange rate changes	-	-	-	-	-
Cash and cash equivalents changes	-	-	-	-	-
Change in working capital	0.04M	0.16M	-0.00207M	0.11M	-0.05112M
Stock based compensation	0.27M	0.06M	0.16M	0.15M	0.14M
Other non cash items	0.05M	-	0.25M	0.21M	-0.18348M
Free cash flow	-2.33198M	-2.46428M	-2.69862M	-1.82018M	-1.11384M

Peer Comparison

Sector: Healthcare Industry: Diagnostics & Research

Company	Change (CAD)	Price (CAD)	Trailing PE (x)	Forward PE (x)	Price Sales TTM (x)	Price to Book Value (x)	Enterprise Value to EBITDA (x)
TELO Telo Genomics Corp	- -%	0.04	-	-	-	8.78	-6.3236
JUMP Leveljump Healthcare Corp	- -%	0.06	3.50	-	0.36	1.00	0.82	8.59
AVCR Avricore Health Inc	- -%	0.06	-	-	3.16	5.09	3.30	41.13
ARC Arian Resources Corp.	- -%	0.01	-	-	2.12	-	15.59	2.25
MBI-H Med BioGene Inc	- -%	0.03	-	-	-	-	-3.032

Reports Covered

View All

Profile

Telo Genomics Corp., a molecular diagnostics company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions, primarily in Canada. The company's TeloView platform measures the 3D structure and spatial organization of telomeres to inform on genetic and molecular characteristics that are predictive of genomic instability, identify specific disease mechanisms, predict disease risks, and determine effective treatments. Its lead product is TeloView-SMM (Smoldering Multiple Myeloma) for SMM patients with a high risk of transition to multiple myeloma (MM). The company also develops TeloView NDMM, which predicts newly diagnosed MM patients who may relapse on first-line therapy; TeloMRD-D, which identifies and enumerates MRD cells in post-transplant patients; and TeloViewNG-MRD (Minimal Residual Disease) Profiling for genomic instability profiling of MRD-detected cells in post-transplant patients. It has a collaboration agreement with the Mayo Clinic. Telo Genomics Corp. is headquartered in Toronto, Canada.

Telo Genomics Corp

555 Richmond Street West, Toronto, ON, Canada, M5V 3B1

647-477-9365
https://www.telodx.com

Key Executives

Name	Title	Year Born
Dr. Sherif Louis MSc, Ph.D., PMP	CEO & Pres	NA
Dr. Sabine Mai Ph.D.	Founder, Member of Clinical & Scientific Advisory Board and Director	NA
Mr. Christopher Ross CPA, CGA	Chief Financial Officer	NA
Dr. Sabine Mai Ph.D.	Founder, Interim CEO, Chair of the Clinical & Scientific Advisory Board and Director	NA
Dr. Sherif Louis MSc, Ph.D., PMP	President & CTO	NA
Mr. Guido Baechler	Executive Chairman	1965
Dr. Hans Knecht M.D.	Medical laboratory Director & Member of Clinical Advisory Board	NA
Dr. Mark Stene M.B.A., Ph.D.	Head of Laboratory Operations	NA
Mr. John Prince	Chief Financial Officer	NA
Mr. John Allen Farlinger C.A.	CEO & Chairman of the Board	1959

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.